Search Results - Jimenez-Zepeda, V.H

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for the treatment of AL amyloidosis: Experience at a single Institution

    Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for the treatment of AL amyloidosis: Experience at a single Institution by Jimenez-Zepeda, V.H, Duggan, P, Neri, P, Bahlis, N

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Pomalidomide-containing regimens for the treatment of relapsed and refractory Multiple Myeloma

    Pomalidomide-containing regimens for the treatment of relapsed and refractory Multiple Myeloma by Jimenez-Zepeda, V.H, Duggan, P, Neri, P, Ahsan, C, Rashid-Kolvear, F, Bahlis, N

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) induction: Impact on Response Rate and MDR negativity for patients with Multiple Myeloma undergoing single auto-SCT

    Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) induction: Impact on Response Rate and MDR negativity for patients with Multiple Myeloma undergoing single auto-SCT by Jimenez-Zepeda, V.H, Duggan, P, Neri, P, Ahsan, C, Luider, J, Bahlis, N

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years

    Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years by Kukreti, V, Maganti, M, Reece, D, Masih-Khan, E, Jimenez-Zepeda, V.H, Trudel, S, Chen, C, Tiedemann, R, Farooki, S

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Identification of predictor factors for Early Relapse (ER) in patients with MM undergoing single auto-SCT

    Identification of predictor factors for Early Relapse (ER) in patients with MM undergoing single auto-SCT by Jimenez-Zepeda, V.H, Duggan, P, Neri, P, Ahsan, C, Luider, J, Rashid-Kolvear, F, Bahlis, N

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Prognostic factors for Overall and Progression-Free Survival in Patients with Multiple Myeloma undergoing single auto-SCT

    Prognostic factors for Overall and Progression-Free Survival in Patients with Multiple Myeloma undergoing single auto-SCT by Jimenez-Zepeda, V.H, Duggan, P, Neri, P, Ahsan, C, Luider, J, Rashid-Kolvear, F, Bahlis, N

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens

    A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens by Kaedbey, R., Dr, Phillips, M, Chung, B, Chen, C.I, Masih-Khan, E, Tiedemann, R.E, Trudel, S, Jimenez-Zepeda, V.H, Kukreti, V, Reece, D.E

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    PF640 MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION‐BASED “IDENTIFYING OUTCOMES IN REAL‐WORLD MULTIPLE MYELOMA” (INFORMM) STUDY

    PF640 MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION‐BASED “IDENTIFYING OUTCOMES IN REAL‐WORLD MULTIPLE MYELOMA” (INFORMM) S... by Jimenez‐Zepeda, V.H., Chen, G., Cowling, T., Shaw, E., Farris, M., Liu, F.F., Tay, J.

    Published in HemaSphere
    Request full text
    Article
    Save to List
    Saved in:

Search Tools: